Related Experiment Video

Updated: Jun 6, 2026

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Beta-adrenergic receptors in cancer: therapeutic implications

Mario Pérez-Sayáns1, José Manuel Somoza-Martín, Francisco Barros-Angueira

  • 1Unidad de Medicina Molecular-Fundación Pública Galega de Medicina Xenómica, Edificio de Consultas planta-2, Hospital Clinico Universitario, Santiago de Compostela, Spain. perezsayans@gmail.com

Oncology Research
|December 15, 2010
PubMed

Insights

The beta2-adrenergic receptor (ADRB2) plays a key role in cancer development, influencing cell growth, metastasis, and tumor progression. Understanding ADRB2

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Oncology

Background:

  • Beta-adrenergic receptors (BARs) mediate cellular responses to catecholamines via G protein signaling.
  • The beta2-adrenergic receptor (ADRB2) is implicated in various cancer-related processes.
  • Existing research links ADRB2 to cell proliferation, apoptosis, chemotaxis, metastasis, tumor growth, and angiogenesis.

Purpose of the Study:

  • To provide an updated review on the role of beta-adrenergic receptors in cancer pathogenesis.
  • To explore the potential therapeutic applications of ADRB2-targeting drugs in cancer treatment.

Main Methods:

  • Literature review of studies investigating ADRB2 in cancer.
  • Analysis of the molecular mechanisms underlying ADRB2's involvement in carcinogenesis.
  • Evaluation of preclinical and clinical data on ADRB2 agonists and antagonists for antitumor therapy.

Main Results:

  • ADRB2 signaling influences critical hallmarks of cancer, including uncontrolled cell proliferation and evasion of apoptosis.
  • ADRB2 expression and activity are associated with enhanced cancer cell migration, invasion, and the development of metastases.
  • The receptor is involved in promoting tumor angiogenesis and growth, further supporting tumor progression.

Conclusions:

  • Beta-adrenergic receptors, particularly ADRB2, are significant modulators of cancer development and progression.
  • Targeting ADRB2 with specific agonist or antagonist drugs presents a promising avenue for novel antitumor therapies.

More Related Videos

Screening Ion Channels in Cancer Cells06:19

Screening Ion Channels in Cancer Cells

Published on: June 16, 2023

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro09:41

Measuring the Rate of Lipolysis in Ex Vivo Murine Adipose Tissue and Primary Preadipocytes Differentiated In Vitro

Published on: March 17, 2023

Related Concept Videos

Adrenergic Receptors (Adrenoceptors): Classification01:27

Adrenergic Receptors (Adrenoceptors): Classification

Adrenergic receptors, or adrenoceptors, respond to the autonomic neurotransmitter noradrenaline and other endogenous catecholamine agonists. They are classified into two main families, α and β, based on their pharmacological response and are further subdivided depending on their location, elicited response, and affinity to specific agonists or antagonists.
α-Adrenoceptors
α-Adrenoceptors are classified into two main subtypes: α1 and α2. The α1 adrenoceptors, which are found on postsynaptic...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors have equal affinities for...
Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...